Ironwood Pharmaceuticals Inc

Latest Results (09.10.2025):

Ironwood Pharmaceuticals Inc reported its second quarter 2025 financial results, demonstrating robust growth in LINZESS® U.S. net sales and significant progress in strategic initiatives aimed at enhancing shareholder value.

LINZESS® U.S. Net Sales

LINZESS® achieved $248 million in U.S. net sales for Q2 2025, marking a 17% increase compared to $211.2 million in Q2 2024. Prescription demand surged by 10% year-over-year, with total prescriptions reaching 58 million capsules.

Financial Performance

Ironwood reported a GAAP net income of $23.6 million in Q2 2025, a substantial improvement from a GAAP net loss of $0.9 million in Q2 2024. Total revenue declined to $85.2 million from $94.4 million year-over-year, while total costs and expenses were significantly reduced to $39.9 million from $69.4 million.

Adjusted EBITDA and Profitability

Adjusted EBITDA for Q2 2025 was $50.1 million, up from $36.5 million in the same quarter last year. Non-GAAP net income stood at $23.6 million, compared to $1.5 million in Q2 2024, reflecting enhanced operational efficiency.

Strategic Initiatives

Ironwood is actively advancing its strategic alternatives review to maximize shareholder value, engaging with Goldman Sachs & Co. LLC. The company also plans to align with the FDA on a confirmatory Phase 3 trial design for apraglutide in Q4 2025, aiming to initiate the trial in the first half of 2026.

Corporate Highlights

The company's collaboration with AbbVie for LINZESS® continues to yield strong results, with net profits from U.S. sales reaching $164.9 million in Q2 2025. Additionally, the commercial margin for LINZESS® improved to 69%, up from 62% in Q2 2024.